Alnylam (NASDAQ: ALNY) CSO sells shares and receives new stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ALNYLAM PHARMACEUTICALS, INC. chief scientific officer Kevin Joseph Fitzgerald reported a mix of stock sales and equity awards. On March 2, 2026, he received a grant of 8,105 stock options and 3,688 shares of common stock represented by restricted stock units that vest in thirds over three years, subject to continued service. The stock options vest over four years, with 25% after one year and the balance in quarterly installments.
Across March 2–3, 2026, he executed open‑market sales totaling 3,250 common shares, some under a mandatory sell‑to‑cover tax provision and under a Rule 10b5‑1 trading plan adopted on August 14, 2025. After these transactions, he directly held 21,860 common shares, 8,105 options, and indirectly held 537 shares through a managed account.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 3,250 shares ($1,051,773)
Net Sell
17 txns
Insider
Fitzgerald Kevin Joseph
Role
CSO & EVP, Head of Research
Sold
3,250 shs ($1.05M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 289 | $316.55 | $91K |
| Sale | Common Stock | 282 | $318.62 | $90K |
| Sale | Common Stock | 722 | $320.51 | $231K |
| Sale | Common Stock | 359 | $321.58 | $115K |
| Grant/Award | Stock Option (right to buy) | 8,105 | $0.00 | -- |
| Grant/Award | Common Stock | 3,688 | $0.00 | -- |
| Sale | Common Stock | 47 | $323.62 | $15K |
| Sale | Common Stock | 90 | $324.65 | $29K |
| Sale | Common Stock | 258 | $325.63 | $84K |
| Sale | Common Stock | 392 | $326.81 | $128K |
| Sale | Common Stock | 329 | $327.67 | $108K |
| Sale | Common Stock | 100 | $328.71 | $33K |
| Sale | Common Stock | 170 | $329.71 | $56K |
| Sale | Common Stock | 81 | $330.85 | $27K |
| Sale | Common Stock | 94 | $331.93 | $31K |
| Sale | Common Stock | 37 | $332.64 | $12K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 23,223 shares (Direct);
Stock Option (right to buy) — 8,105 shares (Direct);
Common Stock — 537 shares (Indirect, by Managed Account)
Footnotes (1)
- These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.16 to $324.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.20 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.21 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.23 to $327.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $327.24 to $328.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.28 to $329.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.29 to $330.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.30 to $331.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.32 to $332.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.34 to $332.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $316.51 to $317.12. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.25 to $318.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.04 to $320.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.36 to $321.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
FAQ
What insider transactions did ALNY CSO Kevin Fitzgerald report on this Form 4 for ALNY?
Kevin Fitzgerald reported a mix of equity awards and sales. He received 8,105 stock options and 3,688 restricted stock units, and sold 3,250 common shares in open‑market transactions over March 2–3, 2026.
What new equity awards did ALNY grant to its CSO Kevin Fitzgerald in this Form 4?
Kevin Fitzgerald was granted 8,105 stock options and 3,688 restricted stock units. The RSUs vest in three equal annual installments over three years, while the options vest over four years, starting with 25% after the first anniversary.